SCHEMBL3079484

SCHEMBL3079484

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2cccc3cccnc23)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.46
RAB9A P51151 2/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
TDP1 Q9NUW8 2/20 0.41
GLO1 Q04760 1/20 0.41
RXFP1 Q9HBX9 4/20 0.41
F2 P00734 2/20 0.41
ENPP2 Q13822 1/20 0.41
EGLN1 Q9GZT9 3/20 0.40
LARS1 Q9P2J5 1/20 0.40
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3097370 0.89 NPC1 (0.51) NPC1RAB9ATP53MAPTLARS1
Hydrochloric Acid SCHEMBL3101058 0.88 NPC1 (0.50) NPC1RAB9ATP53MAPTLARS1
SCHEMBL15000205 0.88 MEN1 (0.46) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL3097268 0.87 LARS1 (0.42) NPC1MAPTMEN1KMT2AF2
SCHEMBL3093039 0.87 MEN1 (0.50) NPC1RAB9ATP53MAPTMEN1
SCHEMBL3093284 0.87 KAT6A (0.49) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL3100534 0.86 KDR (0.43) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL3100518 0.86 NPC1 (0.51) NPC1RAB9ATP53POLBMAPT
SCHEMBL3096503 0.86 LARS1 (0.45) NPC1MAPTMEN1KMT2AF2
SCHEMBL3101165 0.86 NPC1 (0.51) NPC1RAB9ATP53POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 NPC1 3306/4885RAB9A 826/4885CASP3 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.